Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathaniel R Wilson

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|July 6, 2021
Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted TherapyNathaniel R Wilson, Marina Konopleva, Joseph D Khoury, et al.
Leukemia Research|July 12, 2022
Concurrent myelodysplasia and monoclonal B lymphocytosis in VEXAS syndromeNathaniel R Wilson, Preetesh Jain, Jesus A Gomez, et al.
Leukemia & Lymphoma|September 6, 2021
CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignanciesNathaniel R Wilson, Laura Bover, Marina Konopleva, et al.
Leukemia & Lymphoma|May 21, 2024
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging fieldLuan Phan, Danielle Hammond, Nathaniel R Wilson, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|February 22, 2021
Practice patterns and clinical outcomes of platelet alloimmunization in a comprehensive cancer centerRohit V Goswamy, Nathaniel R Wilson, Daniel J Tannenbaum, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 1, 2021
Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysisNathaniel R Wilson, Jonathan R Lockhart, Herney A Garcia-Perdomo, et al.
Leukemia & Lymphoma|March 22, 2021
Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information eraNaveen Pemmaraju, Nathaniel R Wilson, Theresa Clementi Doan, et al.
Current Oncology (Toronto, Ont.)|June 26, 2024
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed StrategyMohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, et al.
Ejhaem|July 18, 2022
Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolismNathaniel R Wilson, Maliha Khan, Travis M Cox, et al.
International Journal of Cancer|March 19, 2021
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experienceOmar Alhalabi, Elshad Hasanov, Nathaniel R Wilson, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Clinical Lymphoma, Myeloma & Leukemia|July 6, 2021
Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted TherapyNathaniel R Wilson, Marina Konopleva, Joseph D Khoury, et al.
Leukemia Research|July 12, 2022
Concurrent myelodysplasia and monoclonal B lymphocytosis in VEXAS syndromeNathaniel R Wilson, Preetesh Jain, Jesus A Gomez, et al.
Leukemia & Lymphoma|September 6, 2021
CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignanciesNathaniel R Wilson, Laura Bover, Marina Konopleva, et al.
Leukemia & Lymphoma|May 21, 2024
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging fieldLuan Phan, Danielle Hammond, Nathaniel R Wilson, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|February 22, 2021
Practice patterns and clinical outcomes of platelet alloimmunization in a comprehensive cancer centerRohit V Goswamy, Nathaniel R Wilson, Daniel J Tannenbaum, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 1, 2021
Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysisNathaniel R Wilson, Jonathan R Lockhart, Herney A Garcia-Perdomo, et al.
Leukemia & Lymphoma|March 22, 2021
Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information eraNaveen Pemmaraju, Nathaniel R Wilson, Theresa Clementi Doan, et al.
Current Oncology (Toronto, Ont.)|June 26, 2024
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed StrategyMohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, et al.
Ejhaem|July 18, 2022
Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolismNathaniel R Wilson, Maliha Khan, Travis M Cox, et al.
International Journal of Cancer|March 19, 2021
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experienceOmar Alhalabi, Elshad Hasanov, Nathaniel R Wilson, et al.
Pageof 4